Need Insurance Coverage?
Learn how to get Zepbound covered by insurance — step-by-step guide to prior authorization, appeals (65%+ success rate), and self-pay options.
Zepbound Article Directory
Explore all our in-depth guides and resources about Zepbound coverage, appeals, and costs.
Denials & Appeals Guide
Understand denials and fight back
Coverage by Insurer
Coverage policies by major insurers
Cost & Savings Options
Reduce your out-of-pocket costs
Alternatives & Comparisons
Compare Zepbound to other treatments
Guides & Indications
Coverage guides and approved uses
Overview
What is Zepbound?
Zepbound (tirzepatide) is the first and only FDA-approved medication that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors for chronic weight management.[2] This once-weekly injection delivered the highest weight loss results in clinical trials among all FDA-approved obesity medications, with patients losing an average of 20.9% of their body weight on the highest dose—and up to 22.5% in some participants.[3]
Injectable GLP-1s: Understanding Your Options
Injectable GLP-1s (Zepbound, Wegovy, Saxenda)
- Administration: Once-weekly (Zepbound, Wegovy) or daily (Saxenda) subcutaneous injection in abdomen, thigh, or upper arm
- Convenience: Requires refrigeration, pre-filled auto-injector pens, smaller needle than insulin
- Efficacy: 8-22.5% weight loss depending on medication and dose (higher than oral options)
- Best for: Patients comfortable with injections seeking maximum weight loss efficacy
Oral GLP-1s (Oral Wegovy & Foundayo Now Available)
- Administration: Once-daily pill, some require 30-minute fasting before eating
- Convenience: No injections or refrigeration, portable, discreet
- Efficacy: Foundayo: up to 12.4% weight loss; Oral Wegovy: ~15% (approaching injectable efficacy)
- Best for: Patients who prefer pills or have needle phobia; Foundayo offers flexible dosing (any time, no food/water restrictions)
Mechanism
How Zepbound Works
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it activates two different hormone pathways involved in blood sugar control and appetite regulation. This dual action distinguishes it from single-target GLP-1 medications like Wegovy or Ozempic.[2]
GLP-1 receptors primarily slow gastric emptying, increase satiety, and reduce appetite. GIP receptors enhance insulin secretion and may improve fat metabolism and energy expenditure. By activating both pathways simultaneously, Zepbound produces greater weight loss than single-target GLP-1 agonists.[2]
GLP-1 and GIP Receptor Activation
- GLP-1 pathway: Slows how quickly food leaves your stomach, increases insulin release when blood sugar is high, reduces glucagon (which raises blood sugar), and decreases appetite signals in the brain.[2]
- GIP pathway: Enhances insulin secretion, may improve how your body uses and stores fat, and potentially increases energy expenditure. The combination of both pathways produces superior metabolic benefits compared to GLP-1 alone.[2]
Why Dual Agonists Work Better: Head-to-Head Comparison
The GIP component enhances metabolic benefits without significantly increasing side effects.[3,4]
Who Might Prefer Zepbound?
- Want maximum efficacy – Seeking the highest possible weight loss (up to 22.5% in trials)
- Failed other GLP-1s – Inadequate results with Wegovy, Saxenda, or Ozempic
- Need aggressive metabolic improvement – High baseline A1C, severe obesity (BMI ≥40), or multiple comorbidities
- Comfortable with weekly injections – Willing to use auto-injector for superior results vs oral options
- Can manage refrigeration – Have reliable cold storage at home and during travel
Dosing Schedule: How Zepbound Is Titrated
Zepbound uses a gradual dose escalation to minimize side effects. Your doctor will increase the dose every 4 weeks based on tolerability:
| Dose | Duration | Purpose |
|---|---|---|
| 2.5 mg | Weeks 1-4 | Starting dose (allows body to adjust) |
| 5 mg | Weeks 5-8 | First therapeutic dose |
| 7.5 mg | Weeks 9-12 | Intermediate dose (optional) |
| 10 mg | Weeks 13-16 | Higher efficacy dose |
| 12.5 mg | Weeks 17-20 | Near-maximum dose (optional) |
| 15 mg | Week 21+ | Maximum dose (up to 22.5% weight loss in trials) |
Note: Many patients achieve good results at 10 mg and may not need to escalate to 15 mg. Your doctor may pause at any dose if side effects are bothersome or if you're achieving your weight loss goals.[2]
Trials & Data
Clinical Evidence
Zepbound's FDA approval was based on the SURMOUNT clinical trial program, which evaluated tirzepatide in over 5,000 participants across multiple Phase 3 studies.
SURMOUNT-1 Trial: Obesity Without Diabetes
SURMOUNT-1 (Adults with obesity or overweight, 72 weeks):[3]
- Mean weight loss: 20.9% (15 mg), 19.5% (10 mg), 15.0% (5 mg) vs 2.4% placebo
- Responder rates (15 mg dose): 96% achieved ≥5% loss, 90% achieved ≥10% loss, 63% achieved ≥20% loss
- Also improved blood pressure, lipids, and inflammatory markers significantly vs placebo
SURMOUNT-2 Trial: Obesity With Type 2 Diabetes
SURMOUNT-2 (Adults with obesity/overweight + T2D, 72 weeks):[6]
- Mean weight loss: 15.7% (15 mg), 13.4% (10 mg) vs 3.3% placebo
- Responder rates: 83% (15 mg) achieved ≥5% weight loss vs 32% placebo
- Significant improvements in A1C, blood pressure, and cardiovascular risk markers
SURMOUNT-OSA Trial: Sleep Apnea
SURMOUNT-OSA (Adults with moderate-severe OSA + obesity, 52 weeks):[7]
- AHI reduction: 62.8% (Study 2, participants on PAP therapy) and 55.0% (Study 1, no PAP)
- Mean weight loss: 18.1% vs 1.3% placebo
- Disease resolution: 51.5% of participants on 15 mg met criteria for OSA resolution
SURMOUNT-5 Trial: Head-to-Head vs Wegovy
SURMOUNT-5 (Tirzepatide vs Semaglutide direct comparison, 72 weeks):[14]
- Mean weight loss: -20.2% (tirzepatide) vs -13.7% (semaglutide)
- Difference: 6.5 percentage points greater weight loss with Zepbound (P<0.001)
- 751 participants randomized to maximum tolerated doses
- First head-to-head comparison of these two leading obesity medications
Published in the New England Journal of Medicine, this trial provides definitive evidence that tirzepatide's dual GIP/GLP-1 mechanism delivers superior weight loss compared to GLP-1-only medications.
Looking for active clinical trials? Search ClinicalTrials.gov for Tirzepatide Studies
Expert Perspective
"Tirzepatide represents a significant advancement in obesity treatment. The SURMOUNT trials demonstrate weight loss comparable to what we typically see only with bariatric surgery, but achieved with a weekly injection. The dual GIP/GLP-1 mechanism appears to offer advantages over single-target therapies."[3]
Key Achievement
In SURMOUNT-1, 96% of patients on the 15mg dose achieved ≥5% weight loss, and 63% achieved ≥20% weight loss — results previously only seen with bariatric surgery.[3]
All Injectable GLP-1 Medications Comparison
| Medication | Route | Weight Loss | Convenience |
|---|---|---|---|
| Zepbound | Weekly injection | 22.5% | Refrigeration required |
| Wegovy | Weekly injection | 15.2% | Refrigeration required |
| Saxenda | Daily injection | 8.0% | Daily dosing, refrigeration |
Safety Profile
Safety and Side Effects
Zepbound's side effect profile is consistent with the GLP-1 drug class, with gastrointestinal symptoms being the most common. In SURMOUNT-1, most adverse events were mild to moderate, and discontinuation rates due to side effects were relatively low (5-7%).[3]
Common Side Effects (SURMOUNT-1 Trial Data)
| Side Effect | Zepbound 15mg | Zepbound 10mg | Placebo | Type |
|---|---|---|---|---|
| Nausea | 31% | 29% | 9% | GI (common) |
| Diarrhea | 21% | 21% | 7% | GI (common) |
| Constipation | 11% | 8% | 5% | GI (common) |
| Vomiting | 10% | 8% | 2% | GI (common) |
| Abdominal pain | 9% | 7% | 4% | GI (common) |
| Dyspepsia | 9% | 8% | 3% | GI (common) |
| Injection site reactions | 7% | 5% | 2% | Local |
| Discontinued due to AEs | 7.1% | 6.9% | 2.5% | — |
Key insight: Most side effects are gastrointestinal, occur during dose escalation, and typically improve with continued use. The gradual titration schedule helps minimize these symptoms.[3]
When to Contact Your Doctor (Serious Warnings)
Seek medical attention if you experience:
- Severe abdominal pain that won't go away (possible pancreatitis)
- Vision changes or difficulty seeing (diabetic retinopathy risk)
- Rapid heartbeat or palpitations while resting
- Lump or swelling in neck, hoarseness, trouble swallowing (thyroid tumor warning)
- Signs of allergic reaction (rash, itching, swelling, difficulty breathing)
- Severe nausea/vomiting preventing you from keeping down fluids
- Severe pain in upper right abdomen (gallbladder problems)
Regulatory Status
FDA Approval Timeline
Eli Lilly received FDA approval for Zepbound (tirzepatide) on November 8, 2023, for chronic weight management in adults with obesity (BMI ≥30, where BMI is body mass index—a measure of weight relative to height) or overweight (BMI ≥27) with at least one weight-related comorbidity (other health condition like type 2 diabetes, high blood pressure, or sleep apnea).[2]
FDA Approved for Sleep Apnea (December 20, 2024): Zepbound became the first-ever pharmaceutical treatment approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.[13] In clinical trials, tirzepatide reduced sleep apnea events (AHI) by 25.3 events per hour compared to just 5.3 with placebo, and up to 50% of adults no longer met diagnostic criteria for OSA after one year. See our full Zepbound for Sleep Apnea guide →
Access & Cost
Insurance Coverage Outlook
Coverage Outlook: Growing Rapidly
Prediction: Coverage will continue expanding through 2026 and beyond as clinical evidence and employer demand grow.
Large employers (5,000+ workers) leading adoption at 43%, with mid-size employers expected to follow.[1]
Coverage Reality Check
Even though Zepbound is FDA-approved for obesity, insurance coverage varies significantly by employer size and plan type. According to the KFF 2025 Employer Health Benefits Survey:[1]
- Very large employers (5,000+ workers): 43% cover GLP-1s for weight loss (up from 28% in 2024)
- Mid-large employers (1,000-4,999 workers): 30% cover for weight loss
- Mid-size employers (200-999 workers): 16% cover for weight loss
Expected Coverage by Plan Type
Commercial Insurance Likely
Obesity indication: Variable by employer size (16%–43% of firms with 200+ workers, 2025)
Estimated copay: $25-$800/month with insurance + manufacturer savings card
Most plans require prior authorization with BMI ≥30 or ≥27 + comorbidity, plus lifestyle modification documentation.
Medicare Part D Changing
Obesity indication: Yes, with conditions, through the Medicare GLP-1 Bridge, a temporary CMS program that runs outside your Part D benefit (July 1, 2026 – December 31, 2027)
Estimated copay: $50 per monthly fill via Medicare GLP-1 Bridge (KwikPen only)
The Medicare GLP-1 Bridge runs July 1, 2026 – December 31, 2027 and covers the Zepbound KwikPen only (not vials or single-dose pens) for obesity at $50 per monthly fill. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization. Eligibility: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD. Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. Outside the Bridge: Basic Medicare Part D coverage excludes drugs used for weight loss. Your Part D plan may cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization. Learn more →
Medicaid Varies
Coverage: Varies by state
Copay: Typically $0-5 if covered
Coverage is volatile—several states (CA, PA, NH, SC) dropped GLP-1 weight loss coverage due to budget pressures. The BALANCE Model for Medicaid: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed. Always verify with your state Medicaid.[8]
TrumpRx (Self-Pay) Available
Status: Launched February 5, 2026
Cost: Lilly’s own self-pay prices, $299–$449/month (no insurance needed)
TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price). Its Zepbound listing is the vial, and orders go through LillyDirect. Self-pay needs no prior authorization and has no income or insurance requirements. Visit TrumpRx.gov →
The Bottom Line
Coverage varies significantly by plan type, employer policies, and pharmacy benefit managers. Don't assume you're not covered — and don't give up if you're denied: you have the right to appeal. Got denied? Here's what to do →
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Your Questions Answered
Frequently Asked Questions
In a head-to-head trial (SURMOUNT-5), Zepbound delivered 20.2% weight loss vs 13.7% for Wegovy—about 47% more effective.[14] Both are once-weekly injections requiring refrigeration, but Zepbound's dual GIP/GLP-1 mechanism produces significantly more weight loss than Wegovy's single GLP-1 mechanism.
Insurance coverage and costs are similar for both medications, though plan formularies may prefer one over the other.
Coverage varies significantly by employer size and plan type. In 2025, 43% of large firms (5,000+ workers) covered GLP-1s for weight loss, compared to only 16% of mid-size firms (200-999 workers).[1]
Medicare: The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Zepbound KwikPen for weight loss at $50 per monthly fill, with conditions. Part D plans may also cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization. Medicaid coverage varies by state and is volatile.[8]
See our complete coverage guide for PA requirements and appeal strategies.
The most common side effects are gastrointestinal: nausea (29-31%), diarrhea (19-21%), vomiting (8-10%), and constipation (8-11%).[3] These are typically mild to moderate and often improve after the first few weeks.
Discontinuation rates due to side effects were relatively low (5-7%) compared to placebo (2.5%). Most people can continue treatment with proper dose titration and symptom management.
With commercial insurance that covers Zepbound + Zepbound Savings Card: as little as $25 for eligible patients.[5]
Without copay card: $200-$800/month depending on your plan's deductible, coinsurance, and tier placement.
Without insurance: about $1,086/month (list price), or $299–$449/month by dose through LillyDirect self-pay (KwikPen or vials). Note: TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price); see TrumpRx.gov. Zepbound, Mounjaro and Foundayo are not on Lilly Cares’ medication list, so Lilly Cares is not a route to free Zepbound.
See our cost guide for savings programs and cost-reduction strategies.
Yes. The same medication (tirzepatide) is sold as Mounjaro for type 2 diabetes and Zepbound for obesity. SURMOUNT-2 trial demonstrated that tirzepatide is safe and effective for weight loss in people with type 2 diabetes, achieving 15.7% weight loss while also improving A1C significantly.[6]
However, you cannot take both Zepbound and Mounjaro simultaneously. Your doctor will prescribe whichever indication is most appropriate for insurance coverage purposes.
Yes. Zepbound pens must be refrigerated (36-46°F / 2-8°C) until first use. After first use, pens can be stored at room temperature (up to 86°F / 30°C) for up to 21 days.[2]
For travel: Use an insulated cooler with ice packs. Most pharmacies can provide travel packs. Plan ahead for extended trips where refrigeration may be unavailable.
Most people begin seeing weight loss within the first 4-8 weeks. In SURMOUNT-1, significant weight loss was evident by week 20, with maximum effects typically seen between 60-72 weeks.[3]
Zepbound follows a dose titration schedule starting at 2.5 mg and increasing every 4 weeks as tolerated, which helps minimize side effects while building toward maximum efficacy.
Yes! On December 20, 2024, Zepbound became the first-ever medication approved by the FDA for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.[13]
In the SURMOUNT-OSA trials, tirzepatide reduced sleep apnea events (AHI) by up to 62.8%, with 51.5% of participants meeting criteria for disease resolution. Up to 50% of adults taking Zepbound no longer met diagnostic criteria for OSA after one year.
Medicare coverage: Your Part D plan may cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization; coverage depends on the plan’s formulary, prior authorization and exceptions process. Basic Part D coverage excludes drugs used for weight loss, but the separate Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Zepbound KwikPen for weight loss at $50 per monthly fill for people who meet CMS's criteria. People with moderate-to-severe OSA aren't eligible for the Bridge, so OSA coverage, if any, comes through your Part D plan.
Impressive and successful!
My doctor did not even try to appeal when zepbound was originally denied, and the thought of appealing myself was overwhelming. I found Honest Care online and was very impressed with the letter and support...
Appeal approved!
I was denied coverage of my zepbound due to my company changed their requirements. After going over the appeal letter with my doctor (she was incredibly impressed) we submitted and got approved within...
Honest Care gets results!
My insurance refused prior authorization for Zepbound, but said I could file an appeal. I received my Appeal was approved the next day. Thank you Honest Care for helping me get my life back.
Explore Other GLP-1 Medications
Compare coverage, costs, and appeal strategies across GLP-1 medications:
References & Further Reading
- KFF. "2025 Employer Health Benefits Survey." Kaiser Family Foundation, October 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
- U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA Press Announcement, November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." *New England Journal of Medicine.* 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/ | SURMOUNT-1 Trial (NCT04184622): https://clinicaltrials.gov/study/NCT04184622
- Garvey WT, Batterham RL, Bhatta M, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." *Nature Medicine.* 2022;28(10):2083-2091. https://pubmed.ncbi.nlm.nih.gov/36216945/
- Eli Lilly and Company. "Zepbound Savings Card Program." Zepbound.Lilly.com, 2025. https://zepbound.lilly.com/coverage-savings
- Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." *The Lancet.* 2023;402(10402):613-626. https://pubmed.ncbi.nlm.nih.gov/37385275/ | SURMOUNT-2 Trial (NCT04657003): https://clinicaltrials.gov/study/NCT04657003
- Eli Lilly and Company. "Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution." Lilly Press Release, June 2024. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-reduced-obstructive-sleep-apnea-osa-severity | SURMOUNT-OSA Trial (NCT05412004): https://clinicaltrials.gov/study/NCT05412004
- Williams E, Rudowitz R, Bell C. "Medicaid Coverage of and Spending on GLP-1s." Kaiser Family Foundation (KFF), November 2024. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
- Pi-Sunyer X, Astrup A, Fujioka K, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." *New England Journal of Medicine.* 2015;373(1):11-22. https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
- Eli Lilly and Company. "FDA Approves Lilly's Zepbound (tirzepatide) for Chronic Weight Management." Lilly Press Release, November 8, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
- Heerspink HJL, Sattar N, Pavo I, et al. "Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial." *The Lancet Diabetes & Endocrinology.* 2022;10(11):774-785. https://pubmed.ncbi.nlm.nih.gov/36150386/
- ClinicalTrials.gov. "Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)." NCT04184622. https://clinicaltrials.gov/study/NCT04184622
- U.S. Food and Drug Administration. "FDA Approves First Medication for Obstructive Sleep Apnea." FDA News Release, December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Aronne LJ, Sattar N, Horn DB, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." *New England Journal of Medicine.* 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- Garvey WT, Mechanick JI, Brett EM, et al. "American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity." *Endocrine Practice.* 2016;22(Suppl 3):1-203. https://pubmed.ncbi.nlm.nih.gov/27219496/
- American Diabetes Association. "Standards of Care in Diabetes—2024: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes." *Diabetes Care.* 2024;47(Suppl 1):S145-S157. https://diabetesjournals.org/care/article/47/Supplement_1/S145/153955
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.
Zepbound (tirzepatide) is an FDA-approved prescription medication. Coverage and access may vary based on your insurance plan, location, and individual medical circumstances. Always verify current coverage with your insurance provider and discuss treatment options with your healthcare team.